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Abstract
Background: Contemporary data remains limited regarding mortality and major adverse cardiac events (MACE) outcomes in
patients undergoing PCI for different manifestations of coronary artery disease.
Objectives: We evaluated mortality and MACE outcomes in patients treated with PCI for STEMI (ST-elevation myocardial
infarction), NSTEMI (non ST-elevation myocardial infarction) and stable angina through analysis of data derived from the
Nobori-2 study.
Methods: Clinical endpoints were cardiac mortality and MACE (a composite of cardiac death, myocardial infarction and
target vessel revascularization).
Results: 1909 patients who underwent PCI were studied; 1332 with stable angina, 248 with STEMI and 329 with NSTEMI.
Age-adjusted Charlson co-morbidity index was greatest in the NSTEMI cohort (3.7861.91) and lowest in the stable angina
cohort (3.0061.69); P,0.0001. Following Cox multivariate analysis cardiac mortality was independently worse in the NSTEMI
vs the stable angina cohort (HR 2.31 (1.10–4.87), p = 0.028) but not significantly different for STEMI vs stable angina cohort
(HR 0.72 (0.16–3.19), p = 0.67). Similar observations were recorded for MACE (,180 days) (NSTEMI vs stable angina: HR 2.34
(1.21–4.55), p = 0.012; STEMI vs stable angina: HR 2.19 (0.97–4.98), p = 0.061.
Conclusions: The longer-term Cardiac mortality and MACE were significantly worse for patients following PCI for NSTEMI
even after adjustment of clinical demographics and Charlson co-morbidity index whilst the longer-term prognosis of
patients following PCI STEMI was favorable, with similar outcomes as those patients with stable angina following PCI.
Citation: Fath-Ordoubadi F, Spaepen E, El-Omar M, Fraser DG, Khan MA, et al. (2014) Outcomes in Patients with Acute and Stable Coronary Syndromes; Insights
from the Prospective NOBORI-2 Study. PLoS ONE 9(2): e88577. doi:10.1371/journal.pone.0088577
Editor: Yan Gong, College of Pharmacy, University of Florida, United States of America
Received August 6, 2013; Accepted January 8, 2014; Published February 14, 2014
Copyright:  2014 Fath-Ordoubadi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Terumo Europe N.V. Leuven, Belgium (www.terumo-europe.com/) provided a research grant but had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr Dragica Paunovic is affiliated to Terumo Europe N.V. Leuven, Belgium, but this does not alter the authors’ adherence to all the PLOS
ONE policies on sharing data and materials. There are no other conflicts of interest to report.
* E-mail: mamasmamas1@yahoo.co.uk
. These authors contributed equally to this work and take responsibility for all aspects of the reliability and freedom from bias of the data presented and their
discussed interpretation.
Introduction
Percutaneous coronary intervention (PCI) has become the
revascularisation therapy of choice in patients with both stable
coronary artery disease and acute coronary syndromes. During the
past few decades, multiple randomised controlled trials have been
undertaken to assess the efficacy of both pharmacological, stent
technology and adjunctive device developments on morbidity and
mortality in both stable and acute coronary syndrome subgroups
of patients [1,2]. However, despite this, contemporary data
remains limited regarding mortality and major adverse cardiac
events (MACE) outcomes when comparing across the spectrum of
patients with different indications for PCI in a ‘‘real-life’’ setting.
For example, similar in-hospital mortality rates have been
described in non ST-elevation myocardial infarction (NSTEMI)
and ST-elevation myocardial infarction (STEMI) in some studies
[3,4] whilst others have reported higher mortality rates amongst
patients with STEMI [5,6]. In the longer term, some studies have
suggested that the prognosis was worse in STEMI as compared to
NSTEMI [7]. Other studies have reported the opposite in the long
term [6] and only few studies have compared the outcome of these
patient groups to those undergoing elective PCI [6]. Studies that
have compared outcomes between STEMI and NSTEMI cohorts
are often difficult to interpret since a significant proportion of
NSTEMI patients may not have received revascularisation in
these studies whilst the majority of patients presenting with
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STEMI do [4,7]. Furthermore, in those studies bare-metal stent
(BMS) and drug eluting stent (DES) usage which is known to
influence MACE rates varies significantly amongst stable and
acute coronary syndrome subgroups of patients [3,8]. This could
further impact outcomes when comparing across the spectrum of
patients with different indications for PCI in a ‘‘real-life’’ setting.
We have therefore evaluated early and late mortality and
MACE outcomes in patients who have been treated with PCI for
STEMI, NSTEMI and stable angina in an all-comer population
through analysis of data derived from a large prospective
multicenter study conducted in 125 centres across Europe and
Asia using only DES - the Nobori-2 study.
Methods
Study Design and Patient Population
Nobori 2 is a prospective, multicenter study conducted in 125
centres across Europe and Asia to investigate the performance of
the Nobori DES system in an all-comers clinical setting [9] with
the only exclusion criterion used being the patient’s refusal or
inability to provide written informed consent. All patients that had
at least one Nobori DES implanted or attempted were included in
the analysis. All patients signed informed consent form reviewed
and approved by the Institutional Review Board or Ethics
Committee of each participating centres. Outcomes were stratified
by indication for PCI; Stable Angina, NSTEMI and STEMI.
Patients presenting with unstable angina were pooled with the
NSTEMI cohort.
Outcomes and Study Definition
ACS was defined as typical symptoms with ischemic electro-
cardiographic changes including ST-segment elevation and non–
ST-segment elevation and/or laboratory evidence of myocardial
damage. All clinical, demographic and outcome data were
collected into a Web-based data management system coordinated
and analyzed by independent companies (KIKA Medical, Paris,
France, and SBD Analytics, Bekkevoort, Belgium, respectively).
Clinical follow-up data included the documentation of adverse
events, in death, MI, repeat revascularisation, stent thrombosis,
bleeding and angina status.
Follow-up was performed at 1 month, 6 months, and 12
months, and yearly up to 5 years. All clinical end points were
adjudicated by an independent clinical events committee. Twelve-
month follow-up rate was 97% and at 2-years was 95%. The
primary end point was cardiac mortality. MACE were defined as a
composite of cardiac death, myocardial infarction (MI) and target
vessel revascularization (TVR).
Statistical Analysis
Continuous variables are presented as mean6standard devia-
tion and were compared using the non-parametric tests: the
Kruskal-Wallis test to compare multiple groups (.2). All tests were
2-sided. Categorical variables are presented as frequencies and
percentages, and were compared using Cochran–Mantel-Haenszel
test or Fisher’s exact test. Kaplan–Meier estimates were generated,
and comparisons of MACE and mortality events were made using
log-rank test. Cox proportional hazards regression was used to
assess pair-wise hazard ratios (HR) of the 3 subgroups under
investigation, either unadjusted (no other covariates) or adjusted
for some selected covariates. The censoring time of a patient for
these time-to-event analyses was defined as the patient’s last
observation time, i.e. follow-up or event time. The proportionality
assumption for the Cox regression models was tested using the
Supremum Test and cumulative score process plots (Cumulative
martingale residuals). In case the proportional hazards assumption
was violated for the main covariate (ACS status), the covariate was
appropriately made time-dependent to maintain proportionality.
Data analysis was performed by an independent statistical office
(SBD Analytics, Bekkevoort, Belgium), using the statistical software
package SAS V8.2 (The SAS Institute, Cary, NC).
Results
The Nobori-2 trial enrolled patients from 125 centres across the
world and 1909 patients were included in this analysis. A total of
1332 patients who underwent PCI had a diagnosis of stable angina
(69.7%) whilst 577 patients were diagnosed with ACS (30.3%). 248
of the patients with ACS presented with STEMI (43%) whilst 329
patients presented with NSTEMI (57%). Clinical demographics
are presented in Table 1. The patients presenting with STEMI
were significantly younger than those presenting with NSTEMI or
stable angina and the age adjusted Charlson co-morbidity index
was greatest in the NSTEMI cohort and lowest in the stable
angina cohort.
Procedural demographics are presented in Table 2, which
demonstrates that the mean number of lesions treated, mean stent
Table 1. Clinical Demographics.
Variable Angina(n=1,332) NSTEMI (n=329) STEMI (n =248) P-Value
Age (mean 6SD) 64.4610.5 65.0611.8 61.3611.8 ,0.0001
Gender (% Male) 1023 (76.8%) 252 (76.6%) 194 (78.2%) 0.89
Hypercholesterolaemia 993 (74.5%) 220 (66.9%) 126 (50.8%) ,0.0001
Hypertension 996 (74.8%) 219 (66.6%) 119 (48.0%) ,0.0001
Diabetes 379 (28.5%) 99 (30.1%) 66 (26.6%) 0.64
Smoker 220 (16.5%) 101 (30.7%) 109 (44.0%) ,0.0001
History of Heart Failure 41 (3.1%) 13 (4.0%) 5 (2.0%) 0.47
Previous AMI 429 (32.2%) 113 (34.3%) 91 (36.7%) 0.35
Previous PCI 487 (37.2%) 70 (21.3%) 29 (11.7%) P,0.0001
Charlson score (mean 6SD) 3.0061.69 3.7861.91 3.2161.66 P,0.0001
*Charlson score (mean 6SD) 1.0661.19 1.7861.31 1.5460.95 P,0.0001
*(without age scoring).
doi:10.1371/journal.pone.0088577.t001
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length and mean number of stents was similar across all 3 groups.
Table 3 illustrates lesion characteristics and QCA analysis of
lesions pre- and post-treatment. Lesion characteristics and type
were similar across the 3 cohorts studied.
Figure 1 illustrates Kaplan-Meier unadjusted survival curves for
cardiac death for all 3 cohorts. A statistically significant increase in
cardiac death was observed in the NSTEMI cohort compared to
the stable angina cohort (unadjusted HR 3.17, 95% CI 1.54–6.53,
p = 0.0017) whereas survival was not statistically different the
STEMI group compared to the stable angina group (unadjusted
HR 0.64 95%CI 0.15–2.78, p = 0.55). Figure 2 illustrates Kaplan-
Meier unadjusted survival curves for MACE for all 3 cohorts. As
the proportionality assumption was violated for the Cox model
with MACE as outcome, Process Score plots were created. These
indicated that a time cut-off around 180 days would reintroduce
proportionality. That is, assessing the effects of ACS status before
and after 180 days separately (but simultaneously model), will yield
valid estimates for each of the time categories, for the ACS status.
Table 2. Procedural Demographics.
Variable Angina (n=1,332) NSTEMI (n =329) STEMI (n =248) P-Value
Glycoprotein IIb/IIIa 185 (14.7%) 92 (27.9%) 98 (39.5%) 0.0001
Radial Access 439 (33.2%) 145 (44.2%) 89 (35.8%) 0.001
Number of vessels diseased 1.7360.78 1.7760.75 1.6860.72 0.42
Number of vessels treated 1.2360.48 1.2660.48 1.2860.53 0.27
Number of lesions detected 1.9761.11 2.1061.11 2.0161.07 0.076
Number of lesions treated 1.4460.77 1.4660.71 1.4860.80 0.62
Number of stents 1.7361.10 1.7160.98 1.8261.19 0.68
Stent Length 33.44622.28 32.48619.94 33.09638.95 0.15
doi:10.1371/journal.pone.0088577.t002
Table 3. Lesion data (data presented per lesion.
Variable Angina (n=1,916) NSTEMI (n=479) STEMI (n =368) P-Value
Target Vessel
RCA 596 (31.1%) 128 (26.7%) 131 (35.6%) 0.021
LAD 746 (38.9%) 186 (38.8%) 167 (45.4%) 0.063
LCx 515 (26.9%) 150 (31.3%) 64 (17.4%) ,0.0001
Left Main 31 (1.62%) 3 (0.63%) 3 (0.82%) 0.199
SVG 28 (1.46%) 12 (2.51%) 3 (0.82%) 0.132
Lesion Characteristics
(n=1,661) (n=438) (n=337)
Ostial lesion 181 (10.9%) 49 (11.2%) 22 (6.5%) 0.037
Bifurcation 329 (19.8%) 87 (19.9%) 52 (15.4%) 0.163
Tortuous 131 (7.9%) 38 (8.7%) 17 (5.05%) 0.122
Calcified 432 (26.0%) 102 (23.3%) 85 (25.2%) 0.518
Lesion Type
A 63 (3.8%) 13 (3.0%) 8 (2.4%) 0.404
B1 403 (24.3%) 93 (21.3%) 79 (23.4%) 0.44
B2 687 (41.3%) 193 (44.2%) 107 (31.8%) 0.001
C 508 (30.6%) 138 (31.6%) 142 (42.1%) 0.0002
QCA Results Pre
Ref vessel diam (mm) 2.6160.60 (1,528) 2.6460.55 (398) 2.6160.58 (252) 0.436
MLD (mm) 0.8760.50 (1,655) 0.7660.45 (436) 0.6160.52 (335) ,0.0001
Lesion Length (mm) 15.6169.93 (1,528) 16.1968.66 (398) 16.4469.71 (252) 0.0504
Diameter stenosis (%) 66.81617.24 (1,655) 71.27616.29 (437) 76.52618.95 (335) ,0.0001
QCA Results Post
Ref vessel diam (mm) 2.8960.51 (1,604) 2.8760.50 (429) 2.9360.49 (321) 0.238
MLD (mm) 2.5160.47 (1,604) 2.5060.47 (429) 2.5460.47 (321) 0.686
Stenosis in stent (%) 13.0766.77 (1,604) 13.0367.44 (429) 13.4267.23 (321) 0.668
doi:10.1371/journal.pone.0088577.t003
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Similarly, a statistically significant increase in MACE was observed
in the NSTEMI cohort compared to the stable angina cohort
(unadjusted HR (#180 days) 3.16, 95% CI 1.70–5.96; P = 0.0004)
whereas MACE was not significantly different in the STEMI
group compared to the stable angina group (unadjusted HR (#
180 days) 5.44 95% CI 0.77–38.67; P = 0.09).
Table 4 illustrates mortality and MACE events for the stable
angina, NSTEMI and STEMI groups at 30 days, 6 months, 1 year
and 2 years. It can be seen that unadjusted 30-day cardiac
mortality rates were higher in the NSTEMI and STEMI groups
compared to the stable angina cohort (0.91%, 0.40% and 0.08%
respectively; P = 0.021), although by two years cardiac mortality
was similar in the STEMI and stable angina cohort but remained
increased in the NSTEMI group (1.13%, 0.81% and 3.95%
respectively; P = 0.0021). Similarly, 30-day unadjusted MACE
events were greater in the NSTEMI and STEMI cohorts at
baseline (2.4%, 1.6% compared to 0.8% in stable angina cohort;
P = 0.039) although by 2 years follow up MACE events were
similar in the stable angina and STEMI cohort but remained
worse in the NSTEMI group (6.5%, 6.8% and 10.3% respectively;
P = 0.048).
Multivariate analysis, using Cox regression, adjusted for clinical
demographics and Charlson score for co-morbidity was performed
for cardiac mortality and MACE events and this is summarized in
Table 5. This demonstrates that after multivariate adjustment,
NSTEMI was independently associated with worse cardiac
mortality compared to the stable angina cohort following
adjustment of baseline clinical demographics and Charlson co-
morbidity score, whilst cardiac mortality and MACE were not
significantly different in the STEMI cohort when compared to the
stable angina cohort.
Discussion
The current analysis was undertaken in patients undergoing
PCI for different manifestations of coronary artery disease such as
high risk acute coronary syndromes (STEMI and NSTEMI) and
stable angina in an all-comer population through analysis of data
derived from a prospective multicenter study conducted in 125
centres across Europe and Asia using a single DES platform. The
main findings of the study were that cardiac mortality and MACE
outcomes of patients following PCI for NSTEMI were significantly
worse than patients undergoing PCI for stable angina, even after
adjustment for baseline clinical demographics and comorbidities
using the Charlson co-morbidity score, whereas longer cardiac
mortality and MACE outcomes of patients following PCI for
STEMI were similar to those following PCI with stable angina
Figure 1. Kaplan-Meier curve for cardiac death.
doi:10.1371/journal.pone.0088577.g001
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following adjustment for baseline clinical demographics and co-
morbidities.
To our knowledge this is one of the first studies that has
compared short and longer-term outcomes in patients undergoing
PCI for different manifestations of coronary artery disease using a
single drug eluting stent platform. Previous studies have shown
that in-hospital mortality rates have been greater in patients
presenting with STEMI than those with NSTEMI [6,7,10,11]
whilst other studies have reported similar in-hospital mortality
rates [4,12]. Similarly at 6 years follow up mortality was greater in
patients presenting with NSTEMI compared to those patients
presenting with STEMI or stable angina in the study of Hirsch
et al [6]. Other studies have shown either worse outcomes in
NSTEMI cohort [11–13] or similar outcomes in STEMI and
NSTEMI patients on longer term follow up [4]. Interpretation of
many of these previous studies is complicated by the observation
that they included patients with NSTEMI and STEMI acute
coronary syndromes who were managed by both PCI or
conservative treatment strategies [4,7,12] with significant differ-
ences in PCI rates in each respective cohort [4,7,12]. Such
differences in the respective revascularisation rate amongst
NSTEMI and STEMI patients has been shown to have significant
implications on longer terms outcomes [7] and so would
significantly bias outcomes previously reported for NSTEMI vs
STEMI cohorts. Furthermore, interpretation of previous studies
comparing outcomes between NSTEMI, STEMI and stable
angina cohorts following PCI are complicated by the fact that
there were significant differences in DES/BMS use between the
cohorts studied which will impact on outcomes [6]. For example,
DES use was infrequent in the study of Hirsch et al. [6] (STEMI
cohort 1%, NSTEMI 8% and stable angina 11%) with the
majority of PCI procedures undertaken with BMS platforms
which is not reflective of contemporary PCI practice where use of
drug eluting stent platforms are much more widespread.
Our findings of worse cardiac mortality and MACE outcomes
associated with patients undergoing PCI for NSTEMI compared
to those with stable angina, with similar longer term MACE and
mortality outcomes in the STEMI vs stable angina cohorts
undergoing PCI is of interest. Whilst patients with NSTEMI
undergoing PCI were older compared to both the STEMI and
stable angina cohorts, which would in itself lend to worse outcomes
in the NSTEMI cohort, the association between NSTEMI and
adverse outcomes persisted even after multi-variate adjustment for
age. Patients presenting with NSTEMI often have a higher
prevalence of cardiovascular and non-cardiovascular co-morbid-
ities compared to patients with STEMI [4,5,12,14,15] and the
presence of such unmeasured confounders has been suggested to
contribute to the adverse outcomes associated with NSTEMI in
Figure 2. Kaplan- Meier curves for MACE.
doi:10.1371/journal.pone.0088577.g002
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previous studies. We have also confirmed that patients presenting
with NSTEMI have a greater prevalence of co-morbid conditions
compared to the STEMI and stable angina cohorts as evidenced
by the greater Charlson co-morbidity score in the NSTEMI
cohort. The Charlson co-morbidity score has been shown to be an
important independent predictor of mortality [16], stent throm-
bosis and major bleeding [17] in patients undergoing PCI.
However, even following adjustment for the presence of co-
morbidities through inclusion of the Charlson score in our
multivariate analysis, NSTEMI was independently associated with
worse cardiac mortality. The worse cardiac mortality outcomes
associated with NSTEMI may relate to residual confounders that
we may not have measured in the older NSTEMI group such as
more severe coronary artery disease in non-revascularised areas of
the coronary vasculature, greater frailty that is a strong predictor
of mortality outcomes following PCI [16] or a greater prevalence
of unmeasured co-morbid conditions that are not included in the
Charlson co-morbidity score.
Whilst the current analysis provides insights into outcomes of
patients undergoing PCI for different manifestations of coronary
artery disease such as ACS (STEMI and NSTEMI) and stable
angina, the findings of our study are not applicable to patients with
stable angina or an ACS who are managed with a non-invasive
strategy. Often these patients are more elderly and have
significantly more cardiovascular and non-cardiovascular co-
morbidities and so may have worse outcomes than reported here
[7]. Indeed, an invasive PCI strategy was independently associated
with a 36% and 49% reduction in 2- year mortality in NSTEMI
and STEMI groups in the study of Polonski et al [7]. Secondly,
information regarding the medical treatment of patients in the
current analysis was not available and so we are unable to
comment on adherence to evidence based therapies in these
cohorts and so are unable to assess the influence of medical
therapy on long-term outcomes. Thirdly, Due to the observational
character of this study and the multitude of analyses performed, it
was not feasible to adjust for multiple testing. As such, we have
supplied nominal p-values, not adjusted for multiple testing.
Finally, the possibility of selection bias cannot be excluded, as the
patients were not consecutively recruited at the study centres.
In conclusion, current analysis undertaken in patients undergo-
ing PCI for different manifestations of coronary artery disease such
as acute coronary syndromes (STEMI and NSTEMI) and stable
Table 4. Clinical outcomes.
Timepoint
Angina
(n=1,332)
NSTEMI
(n =329)
STEMI
(n=248) P-Value
Cardiac Mortality
30-Day 1 (0.08%) 3 (0.91%) 1 (0.4%) 0.021
6 month 2 (0.15%) 5 (1.52%) 2 (0.81%) 0.0041
1 year 10 (0.75%) 10 (3.04%) 2 (0.81%) 0.0044
2 years 15 (1.13%) 13 (3.95%) 2 (0.81%) 0.0021
MACE
30-Day 11 (0.8%) 8 (2.4%) 4 (1.6%) 0.0393
6 month 25 (1.9%) 17 (5.2%) 10 (4.0%) 0.0022
1 year 51 (3.8%) 26 (7.9%) 14 (5.7%) 0.008
2 years 86 (6.5%) 34 (10.3%) 15 (6.1%) 0.048
Myocardial Infarction
30-Day 10 (0.8%) 6 (1.8%) 3 (1.2%) 0.164
6 month 11 (0.8%) 10 (3.0%) 5 (2.0%) 0.0039
1 year 17 (1.3%) 15 (4.6%) 5 (2.0%) 0.0012
2 years 27 (2.0%) 17 (5.2%) 6 (2.4%) 0.01
Target vessel revascularisation
30-Day 2 (0.2%) 3 (0.9%) 2 (0.8%) 0.0328
6 month 14 (1.1%) 8 (2.4%) 7 (2.8%) 0.0288
1 year 32 (2.4%) 13 (4.0%) 11 (4.4%) 0.10
2 years 56 (4.2%) 18 (5.5%) 11 (4.4%) 0.57
doi:10.1371/journal.pone.0088577.t004
Table 5. Unadjusted and adjusted Hazard Ratios and for cardiac death and MACE.
Endpoint Unadjusted OR (95% CI)
Age, Gender adjusted
OR (95% CI)
* Fully adjusted OR (95%
CI)
Cardiac Mortality
NSTEMI vs Stable Angina 3.17 (1.54–6.53), p = 0.0017** 2.84 (1.38–5.87), p = 0.0049** 2.31 (1.10–4.87), p = 0.028**
STEMI vs Stable Angina 0.64 (0.15–2.78), p = 0.55 0.75 (0.17–3.26), p = 0.70 0.72 (0.16–3.19), p = 0.67
NSTEMI vs STEMI 4.92 (1.11–21.74), p = 0.035** 3.77 (0.85–16.66), p = 0.081 3.21 (0.71–14.50), p = 0.13
MACE***
#180 days
NSTEMI vs Stable Angina 3.16 (1.68–5.96), p = 0.0004** 3.06 (1.63–5.76), p = 0.0005** 2.34 (1.21–4.55), p = 0.012**
STEMI vs Stable Angina 2.49 (1.18–5.26), p = 0.017** 2.75 (1.30–5.82), p = 0.008* 2.19 (0.97–4.98), p = 0.061
NSTEMI vs STEMI 1.27 (0.58–2.78), p = 0.55 1.11 (0.51–2.43), p = 0.79 1.07 (0.45–2.54), p = 0.88
.180 days
NSTEMI vs Stable Angina 1.07 (0.63–1.83), p = 0.80 1.04 (0.61–1.78), p = 0.87 0.86 (0.50–1.50), p = 0.60
STEMI vs Stable Angina 0.415 (0.17–1.03), p = 0.058 0.45 (0.18–1.13), p = 0.088 0.46 (0.18–1.14), p = 0.094
NSTEMI vs STEMI 2.59 (0.96–7.01), p = 0.062 2.30 (0.85–6.23), p = 0.10 1.89 (0.69–5.18), p = 0.22
OR corresponds to odds ratio,
*Adjusted for age, gender, hypertension, hypercholesterolaemia, diabetes and Charlson Index.
**equates to statistical significance.
***Time-dependent parameterization of ACS classification for MACE due to non-proportionality - cutoff at 180d.
doi:10.1371/journal.pone.0088577.t005
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angina in an all-comer (‘‘real world’’) population has shown that
NSTEMI presentation is associated with adverse cardiac mortality
and MACE.
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